Alpha Lipoic Acid and Polycystic Ovary Syndrome
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jul 20, 2007
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
Insulin resistance commonly occurs in patients with Polycystic Ovary Syndrome (PCOS) and may be responsible for many of the long term complications of PCOS. Patients with PCOS are at increased risk for developing type 2 diabetes and the metabolic syndrome (hypertension, dyslipidemia and cardiovascular disease). Data suggest that oxidative stress contributes to insulin resistance and thus inhibitors of oxidative stress improve insulin action. Alpha Lipoic Acid (LA) is synthesized in the liver and other tissues and is a key component of several mitochondrial enzyme complexes responsible for o...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • PCOS diagnosis
- • 18 years of age or older
- • Body Mass Index below 35
- • Willing to use any form of contraception for the duration of the study
- Exclusion Criteria:
- • Diabetes
- • Pregnancy
- • Liver or heart disease or other health problems
- • Taking medications that affect insulin resistance
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Umesh Masharani, MD
Principal Investigator
University of California, San Francisco
Ira Goldfine, MD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials